Aquestive Therapeutics, Inc. announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at $4.00 per share, expecting gross proceeds of $85 million. The funds will be used to launch and commercialize Anaphylm™ (epinephrine) Sublingual Film pending FDA approval, as well as for working capital and general corporate purposes. The offering is expected to close on August 15, 2025, led by RTW Investments, LP and other participating firms. Aquestive is focused on advancing medicines through innovative science and delivery technologies, with a strong pipeline of products in development.

The joint bookrunning managers for the offering are Leerink Partners, Cantor, and Oppenheimer & Co., with H.C. Wainwright & Co. as lead manager and Brookline Capital Markets as co-manager. Aquestive has a shelf registration statement on Form S-3 filed with the SEC, and the final prospectus supplement will be available on the SEC’s website. This press release does not constitute an offer to sell securities in any jurisdiction where prohibited by law. Aquestive is committed to bringing meaningful improvements to patients’ lives through innovative pharmaceutical solutions.

Read more at GlobeNewswire: Aquestive Therapeutics Announces Pricing of $85 Million